Human Chorionic Gonadotropin (hCG)
FDA ApprovedA glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
hCG · Choriogonadotropin · Pregnyl · Novarel · Ovidrel · Choragon · Profasi · Choriomon
38 human studies
- Preclinical
- 16%
- Clinical
- 84%
Based on 45 cited sources
clinically demonstrated · high confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 97: Cochrane meta-analyses of multiple RCTs anchor the base (1A=35) — GnRH-agonist-vs-hCG trigger review 25358904 (17 RCTs, n=1,847), rhCG-vs-uhCG review 27106604 (18 RCTs, n=2,952), and cryptorchidism meta-analysis 7673426 (33 studies, 3,282 boys); low-RoB RCTs plus high-confidence AMSTAR-2 reviews (1B=24), total human N >>1,000 (1C=15), direct population/route/outcome match for approved uses (1D=15), solid but human-dominated preclinical base (1E=8). Mechanism 98: LHCGR is a defined receptor with binding + functional + antagonist/genetic confirmation (2A=40), full hCG->LHCGR->Gas->cAMP->PKA->steroidogenesis/ovulation chain mapped (2B=30), in-vivo dose-response (Coviello 15713727 linear ITT across 125/250/500 IU; 2C=18), confirmed in mammalian/human in vivo (2D=10). Plausibility 96: full mechanism->surrogate->clinical chain each independently supported (ovulation->live birth; ITT maintenance->preserved spermatogenesis 23260550; 3A=38), fully coherent with reproductive endocrinology (3B=25), LH/rLH class analogy (3C=19), tightly scoped single-mechanism claim (3D=14). Global Coverage 97: reproduced across many independent groups and countries (Cochrane pools span Europe/Israel/Canada/Australia/US/Egypt; 4A=33, 4B=24), >100 studies and still growing (4C=25), multi-regulator approval FDA + EU (4D=15). Community Experience 82: broad multi-venue TRT-adjunct discussion but niche vs population-scale use (5A=26), >7-year track record (5B=30), broadly consistent themes (5C=16), manageable/isolated adverse signals capping 5D=10. Effectiveness basis clinical (high): gold-standard ovulation trigger with ~88-95% ovulation rates, live-birth superiority over GnRH-agonist trigger in fresh IVF (25358904), hard patient-relevant outcomes, standard of care within its primary indication.
hCG is a well-characterized hormone with extensive human clinical evidence spanning over 50 years. Its mechanisms are firmly established through receptor studies, clinical trials, and decades of therapeutic use.
How It Works (Simplified)
hCG mimics luteinizing hormone (LH) but lasts much longer in the body, providing sustained receptor stimulation:
Binds LHCGR on ovarian follicles, triggering final oocyte maturation and predictable ovulation 36-40 hours post-injection.
Stimulates Leydig cells in testes to produce testosterone, maintaining intratesticular levels critical for spermatogenesis.
Maintains corpus luteum function, ensuring progesterone production needed to support early pregnancy until placental takeover.
Half-life of 24-36 hours (vs LH’s 20 minutes) due to extensive glycosylation and C-terminal extension, enabling single-dose efficacy.
Key Research: Youssef MA et al. Cochrane systematic review (2014) established hCG as gold standard ovulation trigger with higher live birth rates than GnRH agonist in fresh IVF cycles. PMID:25358904
Important Limitations
- OHSS Risk: Primary safety concern; hCG’s sustained LHCGR stimulation can cause ovarian hyperstimulation syndrome in susceptible patients
- Not for weight loss: FDA has warned against hCG use for weight loss (ineffective and potentially harmful)
- Requires monitoring: Fertility applications require physician oversight and ultrasound monitoring
- WADA prohibited: Banned in male athletes due to testosterone-stimulating effects
Reported positives
- Effective for maintaining testicular function during TRT
- Well-established clinical use with decades of data
- Fertility preservation widely confirmed
- Improved mood and sense of wellbeing reported
Reported negatives
- Estrogen elevation requiring management
- Water retention and bloating
- Injection frequency burdensome (multiple times per week)
- Emotional sensitivity and mood swings reported
“Standard component of TRT protocols. Extensively discussed in r/testosterone and HRT communities.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Rapid absorption following subcutaneous injection, with serum hCG rising quickly. Peak serum levels (Tmax) reached around 16-24 hours depending on formulation (urinary vs recombinant).
PMID:35137345Ovulation occurs approximately 36-40 hours post-trigger injection in fertility protocols. This predictable timing enables precise scheduling of egg retrieval or timed intercourse.
PMID:25358904Sustained LHCGR stimulation due to 24-36 hour half-life. In males, testosterone elevation persists for several days. Corpus luteum support maintained through this period.
PMID:15713727With continued administration in TRT protocols, intratesticular testosterone maintained at near-baseline levels. Spermatogenesis preserved with ongoing treatment.
PMID:23260550Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Kisspeptin
SynergisticKisspeptin stimulates endogenous GnRH/LH release while hCG provides direct LHCGR agonism. Combined use studied for ovulation induction with potentially reduced OHSS risk. Clinical trials support sequential administration.
Gonadorelin
SynergisticGnRH pulses restore HPG axis function while hCG provides direct gonadal stimulation. Used sequentially in hypogonadotropic hypogonadism treatment protocols.
Sermorelin
CompatibleDifferent axes of action (GH vs gonadal). No known interactions; commonly used together in hormone optimization protocols.
BPC-157
CompatibleNon-overlapping mechanisms. BPC-157 focuses on tissue repair while hCG acts on gonadal function. No interaction data available.
PT-141
CautionBoth affect reproductive/sexual function through different mechanisms. PT-141 acts on melanocortin receptors while hCG stimulates gonadal hormone production. Monitor for additive effects.
Clomiphene
CautionBoth stimulate gonadal function. Clomiphene via SERM action increasing LH, hCG via direct LHCGR agonism. Combined use requires careful monitoring for overstimulation.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Human Chorionic Gonadotropin (hCG)
Related Peptides
CJC-1295
DAC:GRF · Modified GRF 1-29 · Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST · FS-344 · FS-315 +1
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2 · Pralmorelin · KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6 · SKF-110679 · Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG · Choriogonadotropin · Pregnyl +5
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin · HEX · Growth Hormone Releasing Hexapeptide +2
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.